In 2018, Marsh USA Inc. (Marsh), an insurance company based in New York, launched an innovative pandemic insurance product called PathogenRX. However, until the outbreak of the COVID-19 pandemic in 2020, there was no demand for the product. During the pandemic, some US businesses attempted to claim benefits for business interruption losses from their insurers but were denied because their policies did not cover pandemic losses. Unlike other catastrophic events, pandemics seemed to be uninsurable. In May 2020, industry experts estimated that US small businesses could lose up to US$431 billion due to the COVID-19 pandemic. Marsh's chief executive officer wrote a letter to the United States Congress and president requesting that a state-backed pandemic insurance plan be developed to help cover extremely high potential claim amounts. The federal government could act as a reinsurer and prevent the US insurance industry from collapsing due to increasing claims from US businesses. However, there were several lingering questions: What challenges could be faced in selling pandemic insurance and how could these be resolved? Was it preferable to partner with a government or a private reinsurance partner? How could pandemic insurance modelling be improved to better forecast potential premiums and claims? Arpita Agnihotri is affiliated with Pennsylvania State University - Harrisburg. Saurabh Bhattacharya is affiliated with Newcastle University.

【書誌情報】

ページ数：11ページ

サイズ：A4

商品番号：HBSP-W21048

発行日：2021/2/17

登録日：2021/7/20